title: Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications.
abstract: Leukemia is the most common childhood malignancy and acute lymphoblastic leukemia (ALL) represents the largest sub-type. Despite remarkable improvements over the last 40 years, standard therapy fails in 10-20% of newly diagnosed patients. Survival for children with relapsed ALL is poor, and the development and implementation of novel therapeutic strategies in pediatric ALL are critical to further advancements. Immunotherapeutic approaches have been central to more novel ALL therapies. However, more recent innovation in antibody engineering has improved potency and efficacy, and antibody-drug conjugates (ADCs) are an especially attractive option in severely immunocompromised patients. An even more sophisticated antibody design is that of bi-specific T-cell engaging or BiTE(®) antibodies, which directly recruit effector T cells to augment the anti-neoplastic effect. This review focuses on blinatumomab, a bi-specific anti-CD19/CD3 antibody that has shown efficacy in adult patients with precursor B-ALL and is currently being evaluated in the pediatric setting.
authors.affiliation: The Center for Cancer and Blood Disorders, Children's Hospital Colorado, School of Medicine, University of Colorado Cancer Center , Aurora, CO , USA.
authors.forename: Lindsey M
authors.initials: LM
authors.lastname: Hoffman
authors.affiliation: The Center for Cancer and Blood Disorders, Children's Hospital Colorado, School of Medicine, University of Colorado Cancer Center , Aurora, CO , USA.
authors.forename: Lia
authors.initials: L
authors.lastname: Gore
keywords: T-cell engager; acute lymphoblastic leukemia; bi-specific antibody; drug development; immunotherapy; pediatric leukemia
references.citation: Cancer Immunol Immunother. 2006 May;55(5):503-14
references.pmid: 16032400
references.citation: Leuk Lymphoma. 2011 Jun;52(6):1098-107
references.pmid: 21348573
references.citation: Leukemia. 2003 May;17(5):900-9
references.pmid: 12750704
references.citation: Eur J Haematol. 2013 Oct;91(4):315-21
references.pmid: 23738686
references.citation: Science. 2008 Aug 15;321(5891):974-7
references.pmid: 18703743
references.citation: J Immunol. 2003 Apr 15;170(8):4397-402
references.pmid: 12682277
references.citation: Semin Immunol. 1998 Aug;10(4):267-77
references.pmid: 9695183
references.citation: Int J Cancer. 2005 May 20;115(1):98-104
references.pmid: 15688411
references.citation: Pharmacol Ther. 2012 Dec;136(3):334-42
references.pmid: 22940266
references.citation: J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87
references.pmid: 23852952
references.citation: J Clin Oncol. 2008 Aug 1;26(22):3756-62
references.pmid: 18669463
references.citation: Blood. 2012 Jun 28;119(26):6226-33
references.pmid: 22592608
references.citation: Cancer Res. 2009 Jun 15;69(12):4941-4
references.pmid: 19509221
references.citation: J Clin Oncol. 2012 May 10;30(14):1663-9
references.pmid: 22412151
references.citation: Leukemia. 2008 Dec;22(12):2142-50
references.pmid: 18818707
references.citation: Blood. 2008 Jun 15;111(12):5477-85
references.pmid: 18388178
references.citation: Leukemia. 2008 Jun;22(6):1207-13
references.pmid: 18418410
references.citation: Leukemia. 2011 Jan;25(1):181-4
references.pmid: 20944674
references.citation: Int J Cancer. 2002 Aug 20;100(6):690-7
references.pmid: 12209608
references.citation: Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7021-5
references.pmid: 7624362
references.citation: Curr Opin Mol Ther. 2009 Feb;11(1):22-30
references.pmid: 19169956
references.citation: Blood. 2006 Feb 1;107(3):1116-23
references.pmid: 16195338
references.citation: Blood. 2013 Jun 27;121(26):5154-7
references.pmid: 23678006
references.citation: Nature. 1995 Jul 27;376(6538):352-5
references.pmid: 7543183
references.citation: J Pediatr Hematol Oncol. 2014 Jul;36(5):395-401
references.pmid: 23823112
references.citation: J Clin Oncol. 2010 Jul 1;28(19):3115-21
references.pmid: 20516455
references.citation: Immunobiology. 2009;214(6):441-53
references.pmid: 19157637
references.citation: J Clin Oncol. 2011 Jun 20;29(18):2493-8
references.pmid: 21576633
references.citation: Blood. 2012 Dec 20;120(26):5185-7
references.pmid: 23024237
references.citation: Am Soc Clin Oncol Educ Book. 2013;:294-9
references.pmid: 23714527
references.citation: Exp Cell Res. 2011 May 15;317(9):1255-60
references.pmid: 21419116
references.citation: J Clin Oncol. 2009 Jan 20;27(3):377-84
references.pmid: 19064980
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5175-81
references.pmid: 19805687
references.citation: Cancer Immunol Immunother. 2007 Oct;56(10):1551-63
references.pmid: 17310380